Publication | Open Access

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Her2 AberrationsLung CancersOncologyActionable DriversMedicinePathologyBronchial NeoplasmAnti-cancer AgentCancer TreatmentCancer BiologyCell BiologyLung CancerTumor Biology